Solifenacin

Indication: Overactive bladder Pharmacology: Antimuscarinic Usual Dose: Initial: 5 mg orally once a day Contraindications: Hypersensitivity to solifenacin Urinary retention, gastric retention, uncontrolled narrow-angle glaucoma Warnings: Caution in significant bladder outflow obstruction, decreased GI motility, in patients being treated for narrow-angle glaucoma, renal or hepatic impairment Do not give doses >5 mg if CrCl<30 mL/min or moderate hepatic impairment (Child-Pugh B) Not recommended in severe hepatic impairment (Child-Pugh C) Do not give doses >5 mg if concomitant strong CYP450 3A4 inhibitors Caution in congenital or acquired QT interval prolongation Advise patients about blurred vision, constipation, potential for heat prostration Patients should contact physician if they have severe abdominal pain or are constipated for >=3 days Lactating women should discontinue nursing or discontinue the drug Safety and effectiveness not established in pediatric patients Pregnancy Category: C Side Effects: dry mouth, nausea, vomiting, constipation (e.g. can't poop), dyspepsia urinary tract infection, influenza, pharyngitis dizziness blurred vision, dry eye urinary retention edema, fatigue depression cough hypertension Drug Interactions: ketoconazole strong CYP450 3A4 inhibitors QT interval-prolonging drugs. Vesicare is an extremely expensive drug, avoid purchasing this drug due to it's gigantic cost.

Solifenacin

Clinical data
ATC code	G04BD08 (WHO)
Pharmacokinetic data
Elimination half-life	45 - 68 hours
Identifiers
IUPAC name 1-azabicyclo[2.2.2]oct-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; butanedioic acid
CAS Number	242478-38-2
PubChem CID	443937
DrugBank	APRD00168
CompTox Dashboard (EPA)	DTXSID3048289
Chemical and physical data
Formula	C27H32N2O6
Molar mass	480.553 g/mol

Solifenacin (or Solifenacin succinate) is a urinary antispasmodic.